Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.57 USD
Change Today +0.33 / 1.42%
Volume 319.9K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert L. Coffman Ph.D.

Chief Scientific Officer and Senior Vice President, Dynavax Technologies Corporation
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 3 different industries.

See Board Relationships
68$768,250
As of Fiscal Year 2014

Background*

Dr. Robert L. Coffman, Ph.D. has been Vice President and Chief Scientific Officer at Dynavax Technologies Corporation since December 2000. Dr. Coffman has been Member of Scientific Advisory Board at Genocea Biosciences, Inc., since November 23, 2009. He joined Dynavax Technologies Corporation from the DNAX Research Institute where he had been since 1981, as Distinguished Research Fellow. Dr. Coffman has made fundamental discoveries about the regulation of immune responses ...

Read Full Background

Corporate Headquarters*

2929 Seventh Street
Berkeley, California 94710

United States

Phone: 510-848-5100
Fax: 510-848-1327

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BA
Indiana University, Bloomington
PhD
University of California - San Diego

Other Affiliations*

Annual Compensation*

Salary$440,000
Total Annual Compensation$440,000

Stock Options*

Restricted Stock Awards$42,250
Exercisable Options92,876
Unexercisable Options14,624
Total Number of Options107,500

Total Compensation*

Total Annual Cash Compensation$726,000
Total Short Term Compensation$440,000
Other Long Term Compensation$42,250
Total Calculated Compensation$768,250
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $23.57 USD +0.33

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
J. Joseph Kim Ph.D.Chief Executive Officer, President, Director and Member of Finance Committee
Inovio Pharmaceuticals, Inc.
$964.7K
Douglas J. Swirsky CPA, CFAChief Executive Officer, President, Corporate Secretary and Director
GenVec, Inc.
$375.0K
Jeffrey D. Abbey MBA, J.D.Chief Executive Officer, President and Director
Argos Therapeutics, Inc.
$543.6K
Daniel J. O'Connor Esq.Chief Executive Officer, President and Director
Advaxis, Inc.
$398.8K
William D. Clark Chief Executive Officer, President and Director
Genocea Biosciences, Inc.
$393.6K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.